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Abstract
Background: The present paper is a first evaluation of the use of “CEAwatch”, a clinical support software system
for surgeons for the follow-up of colorectal cancer (CRC) patients. This system gathers Carcino-Embryonic Antigen
(CEA) values and automatically returns a recommendation based on the latest values.
Methods: Consecutive patients receiving follow-up care for CRC fulfilling our in- and exclusion criteria were
identified to participate in this study. From August 2008, when the software was introduced, patients were asked
to undergo the software-supported follow-up. Safety of the follow-up, experiences of working with the software,
and technical issues were analyzed.
Results: 245 patients were identified. The software-supported group contained 184 patients; the control group
contained 61 patients. The software was safe in finding the same amount of recurrent disease with fewer
outpatient visits, and revealed few technical problems. Clinicians experienced a decrease in follow-up workload of
up to 50% with high adherence to the follow-up scheme.
Conclusion: CEAwatch is an efficient software tool helping clinicians working with large numbers of follow-up
patients. The number of outpatient visits can safely be reduced, thus significantly decreasing workload for
clinicians.
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Background
Approximately two-thirds of patients with colorectal can-
cer (CRC) present with potentially curable non-metasta-
sized disease. After completion of treatment, most CRC
patients are followed up to detect recurrence, either local
or distant, at an early, curable stage [1]. In our hospital,
with about 100 new cases of curable CRC a year and 5
years of follow-up with outpatient appointments, the sur-
veillance of such a cohort can accumulate to about 1200
visits, costing a great deal of time and money.
The ideal follow-up for CRC patients has not yet been
settled, although there are national guidelines (http://
www.oncoline.nl) [2]. Since the value of physical
examination in finding recurrent disease is low, there
can be a benefit in reducing outpatient visits. Current
follow-up schemes focus on the most effective combina-
tion of imaging modalities and laboratory measure-
ments. A new strategy is a low-cost ‘triage’ blood
biomarker Carcino-Embryonic Antigen (CEA), which
triggers and directs selective imaging. The keys to the
effective use of CEA are frequent assessment and an
interpretation based on both the absolute value and its
rise [3,4]. The average normal value of serum-CEA is
2.0-2.5 ng/L. The inter-individual variation is approxi-
mately 55% [5], so that every measurement must be
referenced to the previous value.
In our hospital we adhere to a CRC follow-up proto-
col based on CEA testing and outpatient visits every 3
months for the first three years, and every 6 months for
the following two years. If the CEA value is found to
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have increased (>20%), the patient is requested to come
to the laboratory again in 6 weeks. If a large rise (>40%)
is present, or in case of a significant increase two times
in a row, the patient is called up to plan Computed
Tomography (CT) scanning of thorax and abdomen.
Follow-up visits can renew the patients’ worry about the
eventual course of the disease and the outpatient clinic
appointments put a strain on hospital logistics. Since
CEA measurements can be taken in local laboratories
without combining this with an outpatient visit to the
hospital, our follow-up with selective, triggered imaging
can possibly be managed using software support. For
that purpose, we constructed and implemented a soft-
ware system: “CEAwatch”. The aim of this article was to




All patients curatively treated for CRC in our hospital
between January 2004 and January 2010, and receiving
follow-up at the time of the introduction of the software
program, were extracted from the cancer registry data-
base. This search resulted in 331 patients. Eleven
patients (3%) were lost to follow-up, 63 patients (19%)
already had metastatic disease at the introduction of the
software, and 12 patients (4%) were not yet in follow-up
after their resection. As a result, a cohort of 245 patients
was constructed. Data on follow-up were obtained from
the medical records.
Software description
CEAwatch is an intranet-based software system written
to support clinicians working with large numbers of
patients in follow-up. The program was made using
open source internet software: MySQL database, PHP
scripting language, and JAVA programming language. It
is deployed on a server behind the hospital’s firewall.
Entrance to the program is protected with a username
and password. A full description of the software is
added as Additional file 1.
Every day, the program extracts the latest CEA values
of a given list of patients from the hospital information
system and calculates the increase on the last value per
patient. CEAwatch generates letters to patients giving
information about the latest CEA value and its implica-
tions. If the CEA value is steady, the patient is invited to
come to the laboratory again in three or six months; if
the CEA value has increased (>20%), the patient is
requested to come to the laboratory again in 6 weeks. In
case of a significant increase two times in a row or a
large increase after 3 months (>40%), the patient is
called up to plan a CT scan. CEAwatch also suggests a
local laboratory where the patient can have blood
drawn. The clinicians double-check that the letters gen-
erated by CEAwatch fit the patient’s pattern in CEA and
approve the generated letters, which are then printed
and mailed by the secretary of the surgical outpatient
ward.
Follow-up schedule
From 1-8-2008, when the software was introduced,
patients receiving follow-up were asked to participate in
the follow-up using our software system CEAwatch dur-
ing their regular outpatient clinic visit. Patients who
were willing to participate received patient information
before beginning. We refer to this group as the study
group. Those who were not asked or were not willing to
participate served as the reference group. There was no
randomisation between groups, because both groups
received the same follow-up in terms of diagnostics and
imaging, the same follow-up by other specialists (i.e.,
oncologists) if applicable, and clinical management in
case of suspicion of recurrent disease was the same in
the study and reference groups. The only difference was
the use of software between groups; which resulted in
the situation that patients in the study group were seen
at the outpatient clinic once annually instead of four
times a year and they had the possibility of having blood
drawn at local laboratories instead of in the hospital.
These differences were clearly explained to all patients.
Colonoscopy was performed 3 years after the resection
of the primay tumor according to the Dutch guideline
in all patients. In each patient, an annual CT scan of
thorax and abdomen was made. In case of blood sam-
pling at local laboratories, the sample was sent to our
clinic to avoid inter-assay differences. For this goal, we
contacted the external laboratories in our region to send
CEA samples from study patients to our laboratorium.
New eligible patients were added to the database every
week. When the software had been in use for 1.5 years,
all data on both groups were analyzed.
Statistical analysis
The primary goal of this study was to assess the func-
tionality of CEAwatch and the experiences with CEA-
watch of doctors. Interviews were held with the
clinicians; one person (CV) interviewed nine surgeons
using the software, in a face-to-face meeting. The focus
of this interview was on the decrease of workload as a
result of having fewer patients in follow-up at outpatient
clinics. Decrease of workload was expressed in a visual
analogue scale and the interview was constructed by the
authors, including an epidemiologist, using face validity.
Secondary, we were interested in outcomes in terms of
safety in finding metastases and local recurrences. If sus-
picion on metastases and recurrences rose, ascertain-
ment or evaluations by other clinicians beyond the
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surgeons were assessed in both groups if applicable. Dif-
ferences between both groups and follow-up data were




Of the 245 patients in the cohort, 185 patients were
asked between 1-8-2008 and 1-4-2010 by their surgeon
to enter CEAwatch; 184 (75.1%) patients consented.
Sixty-one patients (24.9%) underwent follow-up without
the software support. In Table 1 the CEAwatch group is
compared with the control group regarding baseline
characteristics. There were no differences between age,
sex, or tumour stage between groups. Patients in the
CEAwatch group had less major comorbidity and had
more often rectal cancer.
Efficacy of the software
The software showed few technical problems, which
could all be solved instantly. The amount of time spent
on follow-up patients in regular office hours decreased
sharply, with percentages of up to 50% reported in the
interviews with surgeons. The automatically generated
letters to patients were considered an important relief
and to reduce administration time. As expected, the
number of outpatient clinic visits was significantly lower
in the CEAwatch group. Results for follow-up are
shown in Table 2.
In our control group, an outpatient follow-up control
visit of 15 min is planned, followed by a 5-min tele-
phone call one week later to communicate the CEA
result. As 4 annual visits are planned in the first three
years of follow-up and 2 visits are scheduled in the last
two years of follow-up, the total amount of time per
patient amounts to 5.3 h, i.e., 1067 h for a cohort of 200
patients.
In the study group, outpatient visits were reduced to
once annually. This visit was planned to last 15 min. No
telephone call was necessary, because the CEA commu-
nications are made automatically in writing. Work with
the software consumes about 30 min a week for a
cohort of approximately 200 patients. For the five years
of follow-up, this means 250 h on visits plus 130 h on
the software, resulting in 380 h of work. Thus, the time
saved by the implementation of our software tool
amounts to more than 100 working hours annually.
Outcomes of follow-up
In the study group, 16/184 patients (9%) developed
recurrent disease, occurring in the course of the 1.5
years of follow-up. The study group had a median fol-
low-up time of 2.66 years (range 0.3 - 10.8). Curative
treatment of the recurrent disease was possible in seven
patients out of these sixteen (44%).
In the control group, 8/61 patients (13%) had recur-
rent disease in the course of the intensified follow-up
scheme; the median follow-up was 3.21 years (range 0.1
- 6.1 years). Curative treatment of these metastases/local
recurrences was possible in 1 out of these 8 patients
(12.5%). There was no statistical significant difference in
the curability of recurrent disease between groups.
Discussion
It is known that the implementation of a new guideline
among surgical specialists in a large hospital can be dif-
ficult, and the recent literature shows that software sup-
port increases adherence of the implementation [6,7].
Hereby, clinical decision support-systems using software
appeared to be significantly more effective in improving
clinical practice than systems that relied on manual pro-
cesses [8]. In literature, we did not find any large studies
on the use of software to ameliorate follow-up of color-
ectal cancer patients.
The most important shortcoming of our new system is
of logistic origin. The software was not constructed to
Table 1 Patient and tumour characteristics
CEAwatch Usual care P
Total (N) 184 61 NA
Male (% ) 109 (59) 28 (60) ns
Median age (range) 67.0 (38-87) 70.5 (50-88) ns
Comorbidity (%) Major 20 (11) 14 (25) 0.006
Minor/None 164 (89) 46 (75)
pT (%) 0, 1, or 2 62 (33) 13 (21) ns
3 or 4 121 (66) 47 (77)
unknown 1 (1) 1 (2)
pN (%) 0 119 (65) 32 (52) ns
1 or 2 65 (35) 29 (48)
Location (%) Colon 98 (53) 44 (72) 0.009
Rectum 86 (47) 17 (28)
NA = not applicable, ns = not significant
Table 2 Results of follow-up and clinical visits 1 =
median follow-up time in years, starting from the
introduction of the new follow-up scheme; 2 = number
of outpatient clinical visits to the surgeon for follow-up
of CRC
CEAwatch Usual Care P










Outpatient clinics2 0 (0-7) 3 (0-10) <0.001
Metastases found in follow-up (%) 16 (9) 8 (13) 0.06
Curative metastasectomy 7/16 1/8 0.13
Verberne et al. BMC Medical Informatics and Decision Making 2012, 12:14
http://www.biomedcentral.com/1472-6947/12/14
Page 3 of 5
detect patients’ outpatient visits in other medical fields.
These visits can interfere with the follow-up, and were
noticed later because of the reduction in outpatient vis-
its. We are now working on this by asking patients to
let us know if they have been on other outpatient or
inpatient visits. This has led to a comprehensive
approach to managing the data information and patient
flows in our healthcare environment.
We recognize that our evaluation using structured
interviews with doctors is not evidence-based but based
on our own face validity; all authors have read and
checked the self-constructed interview. Furthermore we
realize that the construction of the groups was not ran-
domized, which can lead to a selection bias. In our view,
the lack of a national evidence-based follow-up scheme
justifies the applied differences between frequencies in
outpatient visits between groups. Hereby a comparison
between the groups does not show differences in
patient’s characteristics nor in tumour stage, which
strengthens our idea that our conclusions are not only
valuable but also statistically solid. The survival per
group did not differ significantly in the first year after
implementation; of course, 3- and 5-year survival curves
will be calculated by the time to evaluate the long-term
outcomes.
The implementation of this software in other hospitals
will be encouraged by the authors. We realize that the
links between the hospital information system and the
software have to be rewritten in the case of other hospi-
tal information systems, but are sure that these are
minor limitations.
Conclusions
We evaluated the experiences with and effectiveness of
follow-up care for patients with colorectal cancer in a
non-randomized study in a consecutive group of
patients using software support, and compared this with
follow-up care without the software. There was a large
decrease in time spent on follow-up, while the safety in
terms of finding curable recurrences was comparable.
Patients’ consent to participate in the software group
was high. The quick provision of information about
the latest CEA value and the possibility of going to a
nearby laboratory were appreciated. We did not per-
form a patients’ satisfaction study, but a study on
patients’ satisfaction was performed by members of
our group (IG, GB) in a pilot trial on frequent CEA
testing in another Dutch hospital. The findings of psy-
chological analysis of patients in this pilot (n = 64)
show a significantly higher level of satisfaction with
the outpatient follow-up scheme compared with the
care usually given (response rate 84%). No significant
differences were found between the trial group and the
comparison group in attitude towards follow-up,
anxiety, depression, and cancer worries.[Reijnen I., I.
Grossmann, P. A. M. Kommers, C. H. C. Drossaert, J.
M. Klaase, T. Wiggers, G. H. de Bock: Positive psycho-
logical evaluation of an intensive follow-up trial in col-
orectal cancer based upon high frequency serum CEA
measurements, Submitted]
The program provides a graphical outline of the
increase in CEA, visible for the doctors working with
the software. This supports the making of clinical deci-
sions for action in follow-up care. Strong features of our
software are the absence of a need for additional data
entry since the software can extract all relevant informa-
tion from the hospital information system, and the inte-
gration with the hospital charting system, which can put
generated patients’ letters back in the system after the
letters being approved, hereby reducing the clinician’s
workload. The use and development of a so-called deci-
sion-support tool is generally a response to poor com-
pliance of clinicians with guidelines [9]; in our hospital
it was constructed to simplify working with large patient
groups receiving follow-up. Computer-based support for
decision making is an accepted independent factor in
improving clinical practice. We found that the software
was easy to use and showed few technical problems. In
interviews with clinicians, we found that the software
tool was well accepted. We recognize that the lack of a
validated interview with surgeons for this purpose is a
weakness of our study design, but constructed the inter-
view carefully with face validity.
The main aim of follow-up is safety in finding meta-
static or local recurrences as soon as possible. We have
found a similar rate of curative options for both groups,
what supports the idea that outpatient visits can safely
be diminished if CEA is closely monitored. We recog-
nize that in this non-randomized study we did not have
the ideal design to enable us to draw conclusions about
this issue. The small number of recurrences may be a
result of the improved preoperative staging over years in
combination with the relatively short period of 1.5 years
in which we evaluated the intensified follow-up scheme.
The safety of our computer-support program has been
proved; further work is now being done and is focused
on finding an accurate and evidence-based follow-up
system, which can then be safely and conveniently sup-
ported by the software constructed (Netherlands Trial
Register: NTR 2182).
Availability and Requirements
All data on availability and Requirements are given in
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Endnotes
The software evaluated in this study was mentioned and
presented at the European School of Oncology class in
Cascais, Portugal, February 2011.
Additional material
Additional file 1: CEA Watch Manual.
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